Masaki Ito

发表

MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.

D. Kufe, R. Stone, D. Raina, 2007, Cancer research.

MUC 1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells

D. Kufe, R. Stone, D. Raina, 2007 .

Fusions between dendritic cells and whole tumor cells as anticancer vaccines

H. Arakawa, H. Tajiri, T. Ohkusa, 2013, Oncoimmunology.

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells

Y. Kamata, K. Hayashi, S. Homma, 2015, BMC Cancer.

Apoptosis in neural crest cells by functional loss of APC tumor suppressor gene

J. Miyazaki, M. Katsuki, T. Noda, 2001, Proceedings of the National Academy of Sciences of the United States of America.

The identification of a novel Paneth cell-associated antigen in a familial adenomatous polyposis mouse model.

S. Homma, Masaki Ito, Y. Sagawa, 2010, Biochemical and biophysical research communications.

Combined TLR2/4-Activated Dendritic/Tumor Cell Fusions Induce Augmented Cytotoxic T Lymphocytes

H. Arakawa, H. Tajiri, T. Ohkusa, 2013, PloS one.

Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer

T. Misawa, H. Arakawa, H. Tajiri, 2014, Clinical Cancer Research.

Antitumor effect of VEGFR2-targeted microbubble destruction with gemcitabine using an endoscopic ultrasound probe: In vivo mouse pancreatic ductal adenocarcinoma model.

K. Sumiyama, H. Imazu, Masaki Ito, 2020, Hepatobiliary & pancreatic diseases international : HBPD INT.

Dendritic/pancreatic carcinoma fusions for clinical use: Comparative functional analysis of healthy- versus patient-derived fusions.

H. Tajiri, T. Ohkusa, M. Mitsunaga, 2010, Clinical immunology.

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation

Y. Kamata, K. Aiba, K. Hayashi, 2016, Cancer science.

Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.

H. Tajiri, T. Ohkusa, Y. Namiki, 2014, Anticancer research.

Nafamostat mesilate, a serine protease inhibitor, suppresses interferon‐gamma‐induced up‐regulation of programmed cell death ligand 1 in human cancer cells

Y. Kamata, S. Homma, Masaki Ito, 2018, International immunopharmacology.

Current Immunotherapeutic Approaches in Pancreatic Cancer

H. Arakawa, H. Tajiri, T. Ohkusa, 2011, Clinical & developmental immunology.

Encryption of agonistic motifs for TLR4 into artificial antigens augmented the maturation of antigen-presenting cells

K. Shiba, K. Hayashi, S. Homma, 2017, PloS one.

Augmentation of Antitumor Immunity by Fusions of Ethanol-Treated Tumor Cells and Dendritic Cells Stimulated via Dual TLRs through TGF-β1 Blockade and IL-12p70 Production

H. Arakawa, H. Tajiri, T. Ohkusa, 2013, PloS one.

Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency

T. Noda, H. Clevers, H. Shibata, 2002, Oncogene.

Combinatorial Contextualization of Peptidic Epitopes for Enhanced Cellular Immunity

K. Shiba, K. Hayashi, S. Homma, 2014, PloS one.

Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines

H. Tajiri, T. Ohkusa, Y. Namiki, 2011, Journal of biomedicine & biotechnology.

Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions

H. Tajiri, T. Ohkusa, Y. Namiki, 2010, Clinical & developmental immunology.

Production of corticotropin-releasing factor and urocortin from human monocyte-derived dendritic cells is stimulated by commensal bacteria in intestine.

H. Arakawa, H. Tajiri, T. Ohkusa, 2014, World journal of gastroenterology.

α-Catenin is essential in intestinal adenoma formation

T. Noda, T. Akiyama, H. Shibata, 2007, Proceedings of the National Academy of Sciences.

Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors.

Y. Kamata, K. Hayashi, S. Homma, 2015, Oncology reports.

Vaccination with vascular progenitor cells derived from induced pluripotent stem cells elicits antitumor immunity targeting vascular and tumor cells

Y. Kamata, K. Hayashi, S. Homma, 2014, Cancer Immunology, Immunotherapy.

Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions

H. Arakawa, H. Tajiri, T. Ohkusa, 2013, Oncoimmunology.

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells

Y. Kamata, K. Hayashi, S. Homma, 2015, BMC Cancer.

Annexin VII as a Novel Marker for Invasive Phenotype of Malignant Melanoma

H. Asada, K. Yoshikawa, Y. Kitamura, 2000, Japanese journal of cancer research : Gann.

Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.

Y. Kamata, K. Hayashi, S. Homma, 2015, Oncology reports.

Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response

H. Tajiri, T. Iwamoto, H. Sugiyama, 2011, Cancer Immunology, Immunotherapy.

Alpha-catenin is essential in intestinal adenoma formation.

T. Noda, T. Akiyama, H. Shibata, 2007, Proceedings of the National Academy of Sciences of the United States of America.

Photodynamic diagnosis of colitis-associated dysplasia in a mouse model after oral administration of 5-aminolevulinic acid.

H. Tajiri, S. Arihiro, Tomohiro Kato, 2013, In vivo.

Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene.

T. Noda, T. Akiyama, H. Shibata, 1997, Science.

Cancer immunotherapy using dendritic/tumour‐fusion vaccine induces elevation of serum anti‐nuclear antibody with better clinical responses

T. Ohno, G. Toda, S. Homma, 2006, Clinical and experimental immunology.

Dendritic/pancreatic carcinoma fusions for clinical use: Comparative functional analysis of healthy- versus patient-derived fusions.

H. Tajiri, T. Ohkusa, M. Mitsunaga, 2010, Clinical Immunology.

Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.

Y. Kamata, K. Hayashi, S. Homma, 2015, Oncology reports.

Immunotherapy synergizes with chemotherapy targeting pancreatic cancer.

H. Tajiri, T. Ohkusa, Y. Namiki, 2012, Immunotherapy.